US 11,904,289 B2
Systems, methods and devices for producing, manufacturing and control of radiopharmaceuticals
Dennis Eshima, Phoenix, AZ (US); Mehmet Husnu, Phoenix, AZ (US); James Stone, Alpharetta, GA (US); Derrick Alcaide, Los Angeles, CA (US); Joseph E. Zambanini, Delaware, OH (US); Thomas A. Klausing, Powell, OH (US); Chad E. Bouton, Powell, OH (US); Henry Padgett, Dublin, OH (US); Brian C. Kelley, Pataskala, OH (US); Scott N. Danhof, Plain City, OH (US); David A. Holley, Lancaster, OH (US); Jeffrey T. Stroup, Upper Arlington, OH (US); James B. Gleeson, Westerville, OH (US); Eric Hassenpflug, Westerville, OH (US); James A. Prescott, Columbus, OH (US); Herman Benecke, Columbus, OH (US); and Daniel B. Garbark, Blacklick, OH (US)
Assigned to Cardinal Health 414, LLC, Dublin, OH (US)
Filed by Cardinal Health 414, LLC, Dublin, OH (US)
Filed on Dec. 22, 2020, as Appl. No. 17/131,420.
Application 17/131,420 is a continuation of application No. 14/871,287, filed on Sep. 30, 2015, granted, now 10,906,020.
Application 14/871,287 is a continuation in part of application No. 14/635,343, filed on Mar. 2, 2015, granted, now 9,480,962, issued on Nov. 1, 2016.
Application 14/635,343 is a continuation of application No. 13/550,026, filed on Jul. 16, 2012, abandoned.
Application 14/871,287 is a continuation in part of application No. 13/550,425, filed on Jul. 16, 2012, abandoned.
Claims priority of provisional application 61/553,029, filed on Oct. 28, 2011.
Claims priority of provisional application 61/508,373, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,359, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,394, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,402, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,349, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,409, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,294, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,382, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,464, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,353, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,374, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,383, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,367, filed on Jul. 15, 2011.
Claims priority of provisional application 61/508,408, filed on Jul. 15, 2011.
Prior Publication US 2021/0187467 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. B01J 19/00 (2006.01); G21G 1/10 (2006.01); A61K 51/04 (2006.01); B65B 3/00 (2006.01); B65B 1/00 (2006.01); G21G 1/00 (2006.01); A61J 3/00 (2006.01)
CPC B01J 19/0006 (2013.01) [A61K 51/0491 (2013.01); B01J 19/004 (2013.01); B65B 1/00 (2013.01); B65B 3/003 (2013.01); G21G 1/10 (2013.01); A61J 3/002 (2013.01); B01J 19/0046 (2013.01); B01J 2219/00049 (2013.01); B01J 2219/0072 (2013.01); B01J 2219/00351 (2013.01); B01J 2219/00355 (2013.01); B01J 2219/00585 (2013.01); B01J 2219/00693 (2013.01); B01J 2219/00702 (2013.01); B01J 2219/00722 (2013.01); B01J 2219/00759 (2013.01); G21G 2001/0015 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A radiopharmaceutical production system comprising:
a cyclotron;
a synthesis unit operatively connected to the cyclotron and to a reagent pack, the synthesis unit comprising at least one modular, disposable cassette unit for receiving a radionuclide from the cyclotron and one or more pharmaceutical reagents from the reagent pack;
a vial filler operatively connected to the synthesis unit for dispensing a radiopharmaceutical produced by the synthesis unit into a vial;
a quality control unit operatively connected to the synthesis unit for performing automated quality control on a sample of at least one dose of the radiopharmaceutical; and
a control platform operatively connected to at least one of the synthesis unit and the quality control unit for receiving therefrom and for associating a unique identifier with each dose of the radiopharmaceutical synthesized by the system.